CT-179 is a potent and selective inhibitor of oligodendrocyte transcription factor 2 (OLIG2), reduces tumor cell proliferation and induces apoptosis, and enhances efficacy when used in combination with radiotherapy and other agents, showing potential in the treatment of medulloblastoma and glioblastoma.

Methods: Daoy, UW228, and Med-813 MB cells were treated with CT-179 (0.01-10 μM, 7 days), and cell viability was determined by MTT assay.
Results: CT-179 showed activity in all three cell lines, with IC50 values ​​of 143.6 nM, 285.4 nM, and 985.2 nM, respectively. [1]

Methods: CT-179 (50 mg/kg, ip, twice weekly for 2 weeks) was combined with RT (8 Gy, 2 Gy fractions) to treat immunocompromised NOD rag γ (NRG) mice implanted with orthotopic Daoy-luci (SHH-MB) to investigate whether it exhibits similar antitumor activity against human MB in vivo.
Results: Animals treated with CT-179 + RT had significantly slower progression and significantly delayed tumor growth in the brain and spinal cord; CT-179 combined with RT significantly prolonged EFS. [1]